XML 50 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Share-Based Compensation (Tables)
 12 Months Ended
Jun. 30, 2016
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted-average assumptions used for grants for the fiscal year ended June 30:

 

     2014  

Risk-free interest rate

      1.6 % 

Expected dividend yield

      0 % 

Expected lives (in years)

      4.1 - 4.7   

Expected volatility

      40 % 
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of option activity is as follows for the fiscal years ended June 30:

 

     2016      2015      2014  
     Number
of
shares		     Weighted
average
exercise
price		      Number
of
shares		     Weighted
average
exercise
price		      Number
of
shares		     Weighted
average
exercise
price		  

Options outstanding at beginning of year

      12.5      $ 23.49         14.2      $ 23.30         14.4      $ 21.75   

Options granted

      —        $ —           —        $ —           3.3      $ 26.52   

Less:

               

Options exercised

      (4.3 )    $ 21.51         (1.2 )    $ 20.17         (3.1 )    $ 19.44   

Options canceled or expired

      —        $ 0.00         (0.5 )    $ 25.98         (0.4 )    $ 24.30   
  

 

 

       

 

 

       

 

 

    

Options outstanding at end of year

      8.2      $ 24.52         12.5      $ 23.49         14.2      $ 23.30   
  

 

 

       

 

 

       

 

 

    

Options exercisable at end of year

      6.7      $ 24.04         9.6      $ 22.80         7.1      $ 21.90   

Options vested and expected to vest

      8.2      $ 24.52         12.5      $ 23.49         13.4      $ 23.12   

Weighted average fair value of options granted during the year

      $ —           $ —           $ 10.04   
Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding and Option Exercisable

The following table summarizes information about stock options outstanding at June 30, 2016:

 

     Options outstanding      Options exercisable  

Range of

exercise

prices

    Number
outstanding
at
June 30,
2016		      Weighted
average
remaining
contractual
life (years)		      Weighted
average
exercise
price		      Number
exercisable
at
June 30,
2016		      Weighted
average
exercise
price		  

$9.04 - 21.29

      2.1         4.55       $ 18.25         2.1       $ 18.25   

21.66 - 26.49

      3.3         4.71         25.32         2.3         24.80   

26.84 - 30.12

      2.2         5.39         27.83         1.8         27.98   

$30.34 - 37.73

      0.6         3.26         30.46         0.5         30.40   
  

 

 

           

 

 

     
     8.2         4.76       $ 24.52         6.7       $ 24.04   
  

 

 

           

 

 

     

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of RSU activity is as follows:

 

     2016      2015  
     Number
of
shares		      Weighted
average
grant date
fair value		      Number
of
shares		      Weighted
average
grant date
fair value		  

RSUs outstanding at the beginning of year

      1.0       $ 37.63         —         $ —     

RSUs granted

      0.8         40.62         1.2         37.66   

Less:

            

RSUs released

      (0.4 )       39.74         —           34.22   

RSUs canceled

      —           —           (0.2 )       38.12   
  

 

 

        

 

 

     

RSUs outstanding at end of year

      1.4       $ 38.76         1.0       $ 37.63   
  

 

 

        

 

 

     

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the consolidated statements of operations for the fiscal years ended June 30, 2016, 2015 and 2014 was as follows:

 

     Years Ended June 30,  
     2016      2015      2014  

Cost of molecular diagnostic testing

    $ 0.9       $ 0.9       $ 0.8   

Cost of pharmaceutical and clinical services

      0.4         0.5         0.3   

Research and development expense

      5.4         4.3         5.4   

Selling, general, and administrative expense

      24.9         40.0         27.5   
  

 

 

     

 

 

     

 

 

  

Total share-based compensation expense

    $ 31.6       $ 45.7       $ 34.0   
  

 

 

     

 

 

     

 

 

  
Schedule of Unrecognized Share-Based Compensation Cost

The Company has unrecognized share-based compensation cost related to share-based compensation granted under its current plans. The estimated unrecognized share-based compensation cost and related weighted average recognition period, aggregate intrinsic value of options outstanding, aggregate intrinsic value of options that are fully vested and aggregate intrinsic value of RSUs vested and expected to vest is as follows:

 

     As of
June 30, 2016		  

Unrecognized share-based compensation cost

    $ 38.2   

Aggregate intrinsic value of options outstanding

      49.6   

Aggregate intrinsic value of options fully vested

      43.9   

Aggregate intrinsic value of RSUs outstanding

    $ 43.5   
Schedule of Intrinsic Value of Options Exercised

The total intrinsic value of options exercised during 2016, 2015 and 2014 was as follows:

 

     Years Ended June 30,  
     2016      2015      2014  

Total intrinsic value of options exercised

    $ 86.1       $ 20.5       $ 49.4   
Schedule of Shares Purchased and Compensation Expenses

Shares purchased under and compensation expense associated with the 1995 and 2012 Plans for the years reported are as follows:

 

     Years Ended June 30,  
     2016      2015      2014  

Shares purchased under the plans

      0.2         0.2         0.2   

Plan compensation expense

    $ 1.9       $ 1.8       $ 1.3   

Employee Stock Purchase Plan  
Schedule of Fair Value of Stock Option Grant Weighted-Average Assumptions

The fair value of shares issued under the Plan that was in effect for each period reported was calculated using the Black-Scholes option-pricing model using the following weighted-average assumptions:

 

     2016     2015     2014  

Risk-free interest rate

      0.4 %      0.1 %      0.1 % 

Expected dividend yield

      0 %      0 %      0 % 

Expected lives (in years)

      0.5        0.5        0.5   

Expected volatility

      31 %      33 %      56 %